SPDR® S&P Biotech ETF (XBI)

82.46
Delayed Data
As of Aug 16
 +2.13 / +2.65%
Today’s Change
64.38
Today|||52-Week Range
100.70
+14.93%
Year-to-Date

Investment Objective

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.

Performance

1 month-6.85% 3 years+8.41%
3 months-2.58% 5 years+9.57%
1 year-13.53% Since inception+12.77%
Data through 08/16/2019

Quote Details

Previous close$80.33
Open day’s range80.80 – 82.55
Net asset value (NAV)80.30 (08/15/2019)
Daily volume3,482,265
Average volume (3 months)4,621,072
Data as of 8:00pm ET, 08/16/2019

Peer Comparisonvs. Health ETFs

 XBICategory
Performance 5-yr return+9.57%+9.15%
Expense Gross exp ratio0.35%1.26%
Risk 5 year sharpe ratio0.510.55
Net assets$4.2B$3.2B
Average market cap$3.4B$36.1B
Average P/E--24.1
Dividend / Share--0.27%

Competitors

FHLC Fidelity MSCI Health Care Index ETF
VHT Vanguard Health Care Index Fund ETF Shar...
IHI iShares U.S. Medical Devices ETF

Holdings

Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
GHDX Genomic Health Inc1.94%
NVTA Invitae Corp1.90%
SRPT Sarepta Therapeutics Inc1.69%
IMMU Immunomedics Inc1.62%
FGEN FibroGen Inc1.58%
NBIX Neurocrine Biosciences Inc1.56%
MRTX Mirati Therapeutics Inc1.53%
BLUE bluebird bio Inc1.52%
ALNY Alnylam Pharmaceuticals Inc1.51%
SGEN Seattle Genetics Inc1.50%